Single-Cell RNA Sequencing Reveals Three Immune Archetypes in Bone Metastases Across Multiple Cancer Types
/in Immunotherapy, mRNA, Preclinical Research/by MaxCD-001: A Promising Novel Dual-Targeting Immunotherapy
/in Immunotherapy, Preclinical Research/by MaxNew Molecule Boosts Vaccine Power Against Cancer and Viruses, In Vivo Study
/in Immunotherapy, Preclinical Research/by MaxAI-Guided Cancer Vaccines Signal a New Era in Personalized Medicine
/in Artificial Intelligence, Immunotherapy, Preclinical Research/by MaxNew Research Unlocks Potential for Immunotherapy in Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxAndrogen Receptor Inhibition Enhances Immune Response in Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxHydrogel Breakthrough May Improve Cancer Vaccines
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxPreclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- Newsletter 17/2026 April 26, 2026
- Not All Patients Benefit Equally: New Score Refines Cabazitaxel Use April 25, 2026
- B7‑H3 Expression Shapes Prognosis Differently Across Prostate Cancer Stages April 24, 2026
- DNA Smart Drugs: Precision Cancer Treatment With a Double Lock April 22, 2026